What is the 13F Pro Quality Score for PEN?

13F Pro ranks Penumbra Inc (PEN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PEN's current score at https://13fpro.ai/company/PEN (free sign-up required for the full ranking).

Which hedge funds own the most PEN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PEN include BlackRock,, HBK INVESTMENTS L P, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/PEN as soon as new 13F filings post.

Where does 13F Pro source PEN data?

All Penumbra Inc fundamentals and ownership data come directly from SEC EDGAR. Penumbra Inc files with the SEC under CIK 1321732. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PEN in?

Penumbra Inc (PEN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives PEN's revenue?

Per Penumbra Inc's latest 10-Q filed with the SEC on 2026-07-30, the biggest revenue drivers are: Thrombectomy ($259.0M, +12.5% YoY); Embolization and Access ($131.1M, +20.0% YoY); United States ($305.4M, +17.1% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/PEN.

What are PEN's largest expenses?

Penumbra Inc's latest 10-Q reports these as the largest expense items: Sales, general and administrative ($198.5M, +24.1% YoY); Cost of revenue ($125.1M, +8.4% YoY); Research and development ($25.4M, +9.4% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is PEN research updated on 13F Pro?

PEN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Penumbra Inc(PEN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1321732 PEN stock profile & AI dashboard →

13F Pro Quality Score

67.1/100

Rank #380 of 2,960 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

71.8/100

Profitability

62.8/100

Balance Sheet

82.9/100

Earnings Quality

79.6/100

Free Cash Flow

64.5/100

Institutional Flow

47.9/100

Revenue Scale

58.1/100

Dilution Risk

27.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why PEN Scores 67/100

exact factor attribution · 2026-09-12

PEN's composite is driven by revenue growth and capital efficiency, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+4.4 pts

72th pct

Capital efficiency

+3.3 pts

83th pct

Earnings quality

+3.0 pts

80th pct

Earnings growth

+2.5 pts

99th pct

Free cash flow

+2.2 pts

65th pct

Profitability

+1.9 pts

63th pct

Scale

+1.2 pts

58th pct

Institutional flow

-0.1 pts

48th pct

Shareholder dilution

-1.1 pts

27th pct

Latest change (2026-08-02): 70 → 66 · ↓ Revenue growth 75→59; ↓ Earnings growth 91→65

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

PEN Stock Analysis & AI Quality Score

Data updated 2026-09-12

AI stock analysis and institutional research for Penumbra Inc (PEN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PEN at 67.1/100 on a 32-signal composite quality model, placing it at rank #380 of 2,960 stocks — the top 25% of the AI-ranked universe. PEN scores in the top quartile across balance sheet strength (82.9), earnings quality (79.6). Shareholder dilution risk is elevated at 27.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Penumbra Inc reports quarterly revenue of $390.0M, net income of $34.8M, an operating margin of 10.5%. Top institutional holders of PEN by reported 13-F value include BlackRock, HBK INVESTMENTS L P, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. PEN trades on the NYSE exchange and files with the SEC under CIK 1321732. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Penumbra Inc directly from SEC EDGAR. Penumbra Inc's 13F Pro composite quality score has ranged between 36 and 72 since 2021, currently 67.1 — an improving long-term trajectory across 69 quarterly and live scoring snapshots.

✦

Fun facts about Penumbra Inc

Quirks, history, and lore behind PEN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on NYSE · headquartered in California.
2
The Numbers
Annual revenue in the range of $200–300 million, built almost entirely on a single category of minimally invasive surgical tools sold to hospitals worldwide.
3
The History
Founded in the early 2000s, it carved out a niche in image-guided therapy — helping surgeons see and treat conditions that were once hard to reach without open surgery.
4
The Secret
Its core technology revolves around atherectomy — using tiny rotating devices to clear calcified plaque from arteries — a procedure that sounds like a dental cleaning for your blood vessels.
5
The Lore
Its flagship product line targets peripheral and coronary artery disease, and the company has invested heavily in intravascular lithotripsy-adjacent and laser-based solutions to bust through the hardest blockages.
6
The Giveaway
Named after the partial shadow cast during an eclipse, this Alameda, CA medtech makes the Jetstream atherectomy system — shining a light into the darkest corners of your arteries.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving PEN's Business? Latest 10-Q Breakdown

✓ 37/37 datapoints verified

AI-extracted from Penumbra Inc's 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue rose 14.9% to $390.0 million and gross margin expanded to 67.9%, but SG&A up 24.1% — including $6.9M of Boston Scientific merger costs — left income from operations flat at $41.0 million.

Biggest Revenue Drivers

Thrombectomy$259.0M+12.5% YoY

Higher sales volume in the United States from further market penetration of existing products; prices substantially unchanged

Embolization and Access$131.1M+20.0% YoY

Higher U.S. sales volume from further market penetration of new and existing products; prices substantially unchanged

Biggest Revenue Drivers

Total revenue: $390.0M+14.9% YoY

Thrombectomy$259.0M+12.5% YoY

Higher sales volume in the United States from further market penetration of existing products; prices substantially unchanged

Within Thrombectomy

United States$305.4M+17.1% YoY

International$84.6M+7.6% YoY

Embolization and Access$131.1M+20.0% YoY

Higher U.S. sales volume from further market penetration of new and existing products; prices substantially unchanged

Largest Expense Items

Sales, general and administrative$198.5M+24.1% YoY

$11.7M higher personnel costs, $6.9M acquisition-related professional services, $6.8M marketing events, $2.7M travel

Cost of revenue$125.1M+8.4% YoY

32.1% of revenue versus 34.0% a year ago

Research and development$25.4M+9.4% YoY

$1.8M more product development and testing, $1.3M personnel, offset by $0.9M lower other R&D on timing

Provision for income taxes$11.4M24.6% effective rate vs 0.1%

Decrease in excess tax benefits from stock-based compensation in the U.S. jurisdiction

Margins: Gross margin rose 1.9 points to 67.9% from 66.0%, primarily driven by favorable product mix across regions. Operating margin fell to 10.5% from 12.0% as SG&A reached 50.9% of revenue.

Watch Items from the Filing

Pending Boston Scientific merger at $374 per share, ~$14.5B enterprise value, expected to close in 2026 subject to regulatory approvals.
Company termination fee of $525.0 million payable to Boston Scientific under specified circumstances; Parent owes $900.0 million in certain cases.
Effective tax rate jumped to 24.6% from 0.1% a year ago, cutting net income to $34.8M from $45.3M despite higher operating income.
International revenue grew only 7.6% versus 17.1% in the U.S., falling to 21.7% of total from 23.2%; no FX hedging in place.
Costa Rica manufacturing project cost estimate increased about $28 million during the six months on design scope refinements; $50.6M paid to date of ~$88M.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$390.0M

Net Income

Q2 2026

$34.8M

Free Cash Flow

Q2 2026

$32.5M

Operating Margin

Q2 2026

10.5%

ROIC

Q2 2026

10.7%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+17.5% YoY

$1.40BFY 2025

FY22 $847.1MFY23 $1.06BFY24 $1.19BFY25 $1.40B

Net Income

+1168.1% YoY

$177.7MFY 2025

FY22 $-2.0MFY23 $91.0MFY24 $14.0MFY25 $177.7M

Operating Income

+1939.5% YoY

$189.2MFY 2025

FY22 $6.1MFY23 $73.6MFY24 $9.3MFY25 $189.2M

EPS (Diluted)

+1155.6% YoY

$4.52FY 2025

FY22 $-0.05FY23 $2.32FY24 $0.36FY25 $4.52

Total Assets

+19.1% YoY

$1.83BFY 2025

FY22 $1.37BFY23 $1.56BFY24 $1.53BFY25 $1.83B

Op. Cash Flow

+41.7% YoY

$238.7MFY 2025

FY22 $-55.7MFY23 $97.3MFY24 $168.5MFY25 $238.7M

Free Cash Flow

+18.8% YoY

$174.9MFY 2025

FY22 $-75.0MFY23 $82.1MFY24 $147.3MFY25 $174.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.40B +17.5%	$1.19B +12.9%	$1.06B +25.0%	$847.1M +13.3%	$747.6M +33.4%	$560.4M
Net Income	$177.7M +1168.1%	$14.0M -84.6%	$91.0M +4643.2%	$-2.0M -137.9%	$5.3M +133.7%	$-15.7M
Operating Income	$189.2M +1939.5%	$9.3M -87.4%	$73.6M +1109.3%	$6.1M +181.1%	$-7.5M +80.7%	$-38.9M
EPS (Diluted)	$4.52 +1155.6%	$0.36 -84.5%	$2.32 +4740.0%	$-0.05 -135.7%	$0.14 +131.8%	$-0.44
Total Assets	$1.83B +19.1%	$1.53B -1.5%	$1.56B +13.5%	$1.37B +10.2%	$1.24B +51.2%	$823.0M
Operating Cash Flow	$238.7M +41.7%	$168.5M +73.1%	$97.3M +274.9%	$-55.7M -685.8%	$9.5M +128.6%	$-33.2M
Free Cash Flow	$174.9M +18.8%	$147.3M +79.4%	$82.1M +209.6%	$-75.0M -541.9%	$-11.7M +79.9%	$-58.0M

Get alerted when PEN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Penumbra Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PEN

BlackRock, Inc.
$1.4B4,297,555 sh
HBK INVESTMENTS L P
$580.5M1,838,508 sh
VANGUARD CAPITAL MANAGEMENT LLC
$539.9M1,709,877 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$526.4M1,667,276 sh
STATE STREET CORP
$392.6M1,243,258 sh
ExodusPoint Capital Management, LP
$344.3M1,090,430 sh
BALYASNY ASSET MANAGEMENT L.P.
$344.2M1,090,163 sh
JPMORGAN CHASE & CO
$338.6M1,071,454 sh
GOLDMAN SACHS GROUP INC
$267.5M847,104 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$263.6M834,903 sh

Fund	Value	Shares
BlackRock, Inc.	$1.4B	4,297,555
HBK INVESTMENTS L P	$580.5M	1,838,508
VANGUARD CAPITAL MANAGEMENT LLC	$539.9M	1,709,877
VANGUARD PORTFOLIO MANAGEMENT LLC	$526.4M	1,667,276
STATE STREET CORP	$392.6M	1,243,258
ExodusPoint Capital Management, LP	$344.3M	1,090,430
BALYASNY ASSET MANAGEMENT L.P.	$344.2M	1,090,163
JPMORGAN CHASE & CO	$338.6M	1,071,454
GOLDMAN SACHS GROUP INC	$267.5M	847,104
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$263.6M	834,903

Companies Similar to PEN

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

NBIX

NEUROCRINE BIOSCIENCES INC

AI score

Similar quality profile · 13 shared holders

Rock Springs Capital Management LP C WorldWide Group Holding A/S PFM Health Sciences, LP

GMED

GLOBUS MEDICAL INC

AI score

Similar quality profile · 17 shared holders

Capital World Investors Holocene Advisors, LP Champlain Investment Partners, LLC

CPRX

CATALYST PHARMACEUTICALS, INC.

AI score

Similar quality profile · 19 shared holders

HBK INVESTMENTS L P GLAZER CAPITAL, LLC WATER ISLAND CAPITAL LLC

BSX

BOSTON SCIENTIFIC CORP

AI score

Similar quality profile · 9 shared holders

Capital World Investors Holocene Advisors, LP Calamos Advisors LLC

TECH

BIO-TECHNE Corp

AI score

Shared smart-money ownership · 29 shared holders

HBK INVESTMENTS L P WHITEBOX ADVISORS LLC TIG Advisors, LLC

STE

STERIS plc

AI score

Similar quality profile · 8 shared holders

Champlain Investment Partners, LLC ING GROEP NV Retirement Systems of Alabama

INCY

INCYTE CORP

AI score

Similar quality profile · 3 shared holders

Retirement Systems of Alabama STATE TREASURER STATE OF MICHIGAN Linden Thomas Advisory Services, LLC

RMD

RESMED INC

AI score

Similar quality profile · 9 shared holders

C WorldWide Group Holding A/S OCCUDO QUANTITATIVE STRATEGIES LP Retirement Systems of Alabama

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PEN on your watchlist

Track score changes the day Penumbra Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PEN a good stock to buy?

13F Pro's AI-powered analysis of Penumbra Inc (PEN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PEN are available on the PEN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PEN is classified as a large company.

Which hedge funds own PEN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PEN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Penumbra Inc's investment landscape.